HIV Drugs Market Size, Share & Trends Analysis Report By Drug Type (Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Entry and Fusion Inhibitors, Combination Class Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2025-2034

HIV Drugs Market Size is valued at 39.29 Billion in 2024 and is predicted to reach 59.74 Billion by the year 2034 at a 4.4% CAGR during the forecast period for 2025-2034.

Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV). The virus damages the immune system and thus interferes with the body’s ability to fight organisms that cause disease. HIV attacks immune cells, specifically CD-4 cells, and makes the body susceptible to infections and other diseases.

AIDS is a life-threatening and chronic disease that can be transmitted from one person to another through various routes, including sexual intercourse, direct injection with HIV-contaminated drugs, needles, syringes, blood or blood products, and from HIV-infected mothers to fetuses. As of now, no cure for AIDS. However, antiretroviral regimens (ARVs) are recommended for patients with HIV as it can dramatically slow the disease progression as well as prevent other infections and complications.

The increasing prevalence of HIV/AIDS worldwide catalyzes the growth of the global HIV drugs market. According to UNAIDS, in 2019, the total number of patients with HIV/AIDS was around 38 million across the globe. The adult and children population was 36.2 and 1.8 million, respectively.

Additionally, several initiatives are undertaken by governments/associations/organizations in respective countries and globally to educate and raise awareness, availability of generic HIV drugs, and new drug development and regulatory approvals for HIV treatment are expected to drive the market further. For instance, in March 2020, ViiV Healthcare, the subsidiary of GlaxoSmithKline, received regulatory approval for its long-acting regimen for the treatment of HIV; CABENUVA by Health Canada.

Competitive Landscape

Some Of The key players in the Global HIV Drugs Market:

·       Gilead Sciences

·       ViiV Healthcare

·       Johnson & Johnson (Janssen)

·       Merck & Co.

·       AbbVie

·       Boehringer Ingelheim

·       Roche

·       Cipla

·       Teva Pharmaceuticals

·       Emcure Pharmaceuticals

·       AstraZeneca

·       Bristol-Myers Squibb

·       Daiichi Sankyo

·       Hetero Drugs

·       Viatris (Mylan)

·       Aspen Pharmacare

·       AELIX Therapeutics

·       Excision BioTherapeutics

·       HOOKIPA Pharma

·       Immuno Cure BioTech

·       Immunocore

·       Sumagen

·       OyaGen

·       Quality Chemical Industries

·       Lyndra Therapeutics

Market Segmentation

The Global HIV drugs market is segmented on the basis of drug type and distribution channel. By Drug Type (Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Entry and Fusion Inhibitors, Combination Class Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).

Based on the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market in 2024, followed by Europe and Asia Pacific. On the other hand, the Asia Pacific is projected to have the highest growth rate during the forecast period.

The HIV Drugs Market Report Scope

Global HIV Drugs Market Segmentation:

Global HIV Drugs Market By Drug Class

·       Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

·       Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

·       Protease Inhibitors (PIs)

·       Integrase Strand Transfer Inhibitors (INSTIs)

·       Entry Inhibitors

·       Fusion Inhibitors

·       Pharmacokinetic Enhancers

·       Fixed-Dose Combination Drugs

·       Long-Acting and Novel Therapies

Global HIV Drugs Market By Regimen Type

·       Single-Tablet Regimens

·       Multi-Tablet Regimens

·       Long-Acting Injectables

By Line of Therapy

·       First-Line Therapy

·       Second-Line Therapy

·       Maintenance Therapy

·       Salvage Therapy

By Route of Administration

·       Oral

·       Injectable

·       Implant

By Brand

·       Branded Drugs

·       Generic Drugs

By Patient Group

·       Adults

·       Pediatrics

·       Pregnant Women

By End User

·       Government and Public Health Programs

·       Private Hospitals and Clinics

·       Retail Pharmacies

·       Online Pharmacies

·       NGOs and Humanitarian Programs

Global HIV Drugs Market Revenue (US$ Mn), By Region,

North America HIV Drugs Market Revenue (US$ Mn), by Country, 

• U.S.
• Canada

Europe HIV Drugs Market Market Revenue (US$ Mn), by Country,

• U.K.
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific HIV Drugs Market Revenue (US$ Mn), by Country, 

• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America HIV Drugs Market Revenue (US$ Mn), by Country,

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa HIV Drugs Market Revenue (US$ Mn), by Country,

• GCC Countries
• South Africa
• Rest of Middle East & Africa